Mission Statement
• To help people with intestinal and/or urinary diversions to lead full and productive lives and to provide information and emotional support to their families and caregivers.
• To educate the public about intestinal and urinary diversion surgery.
• To provide trained visitors to those who have undergone intestinal and/or urinary diversions, including preoperative and postoperative visits or phone calls, at the request of the physician or enterostomal therapist.
Meetings
Fall meeting schedule:
September 13th/11 - Welcome/Coloplast representative
October 11th - Convatec respresentative
November 8th - seniors healthy living program presentation
December 13th - turkey supper - Pasqua hospital
Special Events
We are once again planning a full day seminar to be held May 5th, 2012. More details will be forthcoming.
News and Research
Detecting colorectal cancer in its early, curable stages is the goal behind Phenomenome Discoveries Inc.'s licensing of a diagnostic blood test in Saskatchewan.
Colorectal cancer is the second most commonly diagnosed cancer and the second leading cause of cancer death in both men and women. Every year approximately 650 people are diagnosed with colorectal cancer in this province and 250 people die from the disease. Phenomenome Discoveries Inc.'s test measures blood levels of a novel metabolite that is low in people with colorectal cancer.
"This is an encouraging development right here in Saskatchewan that will help with the early detection of cancer," Premier Brad Wall said. "This has the potential to make a big difference to Saskatchewan people dealing with cancer."
"Determining cancer risk through a blood test has the potential to strengthen cancer care for Saskatchewan people, something that is a high priority for our government," Health Minister Don McMorris said.
The trial for the blood test took place over two years and involved more than 5,000 patients in the Regina Qu'Appelle Health Region. The results of this clinical trial indicate that the test led to the diagnosis of 87 per cent of early stage cancers, making it the most sensitive blood test available for colorectal cancer.
"Colorectal cancer is more than 90 per cent preventable and easily treated when found in the early stages," Saskatchewan Cancer Agency Chief Executive Officer Scott Livingstone said. "Finding ways to detect and prevent the disease is an important aspect of our work in the fight against cancer."
"We are pleased to be able to detect such high rates of early stage colorectal cancer using a non-invasive blood test, and that Saskatchewan will be the first province to license the right to use it," Phenomenome Discoveries Inc. Chief Executive Officer Dr. Dayan Goodenowe said.
Saskatchewan has made reducing colorectal cancer mortality a priority. Continuing to expand screening programs that detect early stage cancer is the best way to achieve this goal, allowing Saskatchewan to
maintain a leadership role in cancer screening.